Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer...
Vous n'êtes pas connecté
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 04/Nov 13:20
Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly improve the outlook for women diagnosed with this aggressive disease. Ovarian cancer is the most lethal gynaecological cancer in the world, with an abysmal survival rate, mainly due to late diagnosis. Each year, more than 200,000 women die [...]
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer...
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer...
Researchers at the University of California, San Diego School of Medicine, USA, have identified a promising new therapy for triple-negative breast...
Researchers at the University of California, San Diego School of Medicine, USA, have identified a promising new therapy for triple-negative breast...
Australian scientists have discovered that an existing lymphoma drug, romidepsin, can break through treatment resistance in relapsed neuroblastoma,...
Australian scientists have discovered that an existing lymphoma drug, romidepsin, can break through treatment resistance in relapsed neuroblastoma,...
CNN — Charmella Roark remembers the shock that stopped her in her tracks when she learned about her younger sister’s cancer diagnosis. In...
CNN — Charmella Roark remembers the shock that stopped her in her tracks when she learned about her younger sister’s cancer diagnosis. In...
More than 10 women under 50 will be diagnosed with breast cancer every day in Australia this year as a rise in younger people developing the disease...
Studies have shown that nearly 60% of breast cancer cases in India are diagnosed at Stage III or IV, with the 5-year survival rate for Stage IV...